-+ 0.00%
-+ 0.00%
-+ 0.00%

Morgan Stanley Maintains Overweight on BioMarin Pharmaceutical, Raises Price Target to $124

Benzinga·08/07/2026 18:48:33
Listen to the news
Morgan Stanley analyst Matthew Harrison maintains BioMarin Pharmaceutical (NASDAQ:BMRN) with a Overweight and raises the price target from $119 to $124.